Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia
Article in Diagnostics (May 2023)
The most recent citing publications are shown below. View all 75 publications that cite this research output on Dimensions.
Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy
Article in Pharmacognosy Journal (January 2023)
p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
Article in F1000Research (November 2022)